Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review. Issue 1 (1st March 2021)

• Record Type: Journal Article
• Authors: Belleudi, Valeria; Marchetti, Federico; Finocchietti, Marco; Davoli, Marina; Addis, Antonio
• Is Part Of: BMJ paediatrics open. Volume 5:Issue 1(2021)
• Publication Date: 2021-03-01
• Subjects: pharmacology -- neonatology -- therapeutics; Pediatrics -- Periodicals; Children -- Health and hygiene -- Periodicals; 618.920005
• DOI: 10.1136/bmjpo-2020-000985
• Languages: English
• ISSNs: 2399-9772

Abstract

Abstract : In Italy, reimbursement restrictions regarding palivizumab prophylaxis approved in 2016 have been revoked in 2017, restoring use in infants with Gestational Age (GA) >29 weeks. Respiratory Syncytial Virus (RSV) hospitalisations and prevalence of palivizumab use in infants aged <6 months during five seasons (2014–2019), were considered according to different GA. Although RSV hospitalisations rate showed no significant changes, during different seasons in all GA, lower prevalence of palivizumab use in 2016 (0.8% vs 0.3%), returned to a higher level following the revoke of restrictions. Changes in reimbursement criteria were not associated with neonatal RSV hospitalisations rate but with a significant impact on palivizumab use.